The University of Texas M.D. Anderson Cancer Center is a freestanding, categorical academic institution established within the University of Texas System by the Texas legislature in Houston in 1941. In 1954, the M.D. Anderson was moved to its current location in the Texas Medical Center in close proximity to other leading biomedical research institutions. The mission of the M.D. Anderson is to eliminate cancer and allied diseases as significant health problems throughout Texas, the nation and the world by developing and maintaining integrated quality programs in patient care, research, education and prevention. M.D. Anderson is dedicated wholly to the study of cancer involving a continuum of research in the basic sciences, clinical investigations and population- based research, with an emphasis on multi-disciplinary translational activities. Faculty investigators are engaged in the transfer of new technology and basic laboratory advances to the clinic, in providing cutting-edge clinical programs including both inpatient and outpatient care, and in community outreach aimed primarily at screening and early detection. The research activities of M.D. Anderson are organized into 28 research programs which include 7 basic science research programs, 18 clinical research programs consisting of 11 disciplinary disease-site programs and 7 thematic programs, and 3 population-based research programs as described in this renewal. The research is supported by the 13 CCSG Core Facilities described in the application for which funding is requested These include 11 currently funded facilities: Automated Cytometry and Cell sorter/Confocal Microscopy and Image Analysis, High Resolution Electron Microscope. Tissue Procurement and Banking, Centralized Histopathology, Research Animal Support, Veterinary Research Support, Cancer Information Systems, Biostatistical Resource Group, Macromolecular Analysis, Synthetic Antigen Laboratory, and Clinical Trials Support, as well as two new facilities, the Pharmacology and Analytical Center and a Central Media Laboratory. Funds are also requested for the Protocol Review and Monitoring System, for Center and a Central Media Laboratory. Funds are also requested for the Protocol Review and Monitoring System, for Development, Planning and Evaluation, and for partial salary support for Senior Leadership and Program Directors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016672-26S1
Application #
6503832
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
1978-07-01
Project End
2003-06-30
Budget Start
2001-08-01
Budget End
2002-06-30
Support Year
26
Fiscal Year
2001
Total Cost
$87,716
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
Other Domestic Higher Education
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Dutcher, Giselle M A; Bilen, Mehmet Asim (2018) Therapeutic Vaccines for Genitourinary Malignancies. Vaccines (Basel) 6:
Kurnit, Katherine C; Dumbrava, Ecaterina E Ileana; Litzenburger, Beate et al. (2018) Precision Oncology Decision Support: Current Approaches and Strategies for the Future. Clin Cancer Res 24:2719-2731
Duplisea, Jonathan J; Mokkapati, Sharada; Plote, Devin et al. (2018) The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside. World J Urol :
Jordan, V Craig (2018) Tamoxifen Resistance Trumped and Oral Selective Estrogen Receptor Degraders Arrive. Clin Cancer Res 24:3480-3482
Pantano, Naitielle; Hunt, Brady; Schwarz, Richard A et al. (2018) Is Proflavine Exposure Associated with Disease Progression in Women with Cervical Dysplasia? A Brief Report. Photochem Photobiol 94:1308-1313
Mehrvarz Sarshekeh, Amir; Xiong, Henry Q; Iizuka, Kenzo et al. (2018) Phase II study of DFP-10917, a deoxycytidine analog, given by 14-day continuous intravenous infusion for chemotherapy-refractory advanced colorectal cancer. Invest New Drugs 36:895-902
Lang, Frederick F; Conrad, Charles; Gomez-Manzano, Candelaria et al. (2018) Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma. J Clin Oncol 36:1419-1427
Ishizawa, Jo; Nakamaru, Kenji; Seki, Takahiko et al. (2018) Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition. Cancer Res 78:2721-2731
Talluri, Rajesh; Shete, Sanjay (2018) An approach to estimate bidirectional mediation effects with application to body mass index and fasting glucose. Ann Hum Genet 82:396-406
Bhadra, Anindya; Rao, Arvind; Baladandayuthapani, Veerabhadran (2018) Inferring network structure in non-normal and mixed discrete-continuous genomic data. Biometrics 74:185-195

Showing the most recent 10 out of 12418 publications